1. Home
  2. NETD vs CADL Comparison

NETD vs CADL Comparison

Compare NETD & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NETD
  • CADL
  • Stock Information
  • Founded
  • NETD 2023
  • CADL 1999
  • Country
  • NETD United States
  • CADL United States
  • Employees
  • NETD N/A
  • CADL N/A
  • Industry
  • NETD
  • CADL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NETD
  • CADL Health Care
  • Exchange
  • NETD Nasdaq
  • CADL Nasdaq
  • Market Cap
  • NETD 240.8M
  • CADL 265.7M
  • IPO Year
  • NETD 2023
  • CADL 2021
  • Fundamental
  • Price
  • NETD $11.20
  • CADL $5.63
  • Analyst Decision
  • NETD
  • CADL Strong Buy
  • Analyst Count
  • NETD 0
  • CADL 6
  • Target Price
  • NETD N/A
  • CADL $20.33
  • AVG Volume (30 Days)
  • NETD 3.2K
  • CADL 718.8K
  • Earning Date
  • NETD 01-01-0001
  • CADL 11-13-2025
  • Dividend Yield
  • NETD N/A
  • CADL N/A
  • EPS Growth
  • NETD N/A
  • CADL N/A
  • EPS
  • NETD 0.29
  • CADL N/A
  • Revenue
  • NETD N/A
  • CADL N/A
  • Revenue This Year
  • NETD N/A
  • CADL N/A
  • Revenue Next Year
  • NETD N/A
  • CADL N/A
  • P/E Ratio
  • NETD $38.09
  • CADL N/A
  • Revenue Growth
  • NETD N/A
  • CADL N/A
  • 52 Week Low
  • NETD $10.64
  • CADL $3.79
  • 52 Week High
  • NETD $11.47
  • CADL $14.60
  • Technical
  • Relative Strength Index (RSI)
  • NETD 45.01
  • CADL 55.95
  • Support Level
  • NETD $11.21
  • CADL $5.38
  • Resistance Level
  • NETD $11.23
  • CADL $5.76
  • Average True Range (ATR)
  • NETD 0.02
  • CADL 0.30
  • MACD
  • NETD -0.01
  • CADL 0.08
  • Stochastic Oscillator
  • NETD 0.00
  • CADL 86.46

About NETD Nabors Energy Transition Corp. II

Nabors Energy Transition Corp II is a blank check company.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: